Focus: Olympus is a public biotechnology company headquartered in Center Valley, PA, specializing in surgical products and imaging technologies across oncology, gastroenterology, respiratory, women's health, and endocrinology. With 201-500 employees, it operates as a mid-cap medical device and therapeutic innovator.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Olympus offers meaningful exposure to surgical innovation and multi-modal therapeutics, but tight hiring and regulatory headwinds make it a higher-risk career move unless seeking deep device engineering or niche regulatory expertise.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Olympus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Olympus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Zai Lab Ltd (ZLAB) (CIK 0001704292) — EX-99.1
EX-99.1
Rafferty Domnick Cunningham & Yaffa On What the FDA’s Latest Warning to Olympus Means for Medical Device Accountability - The Manila Times
Rafferty Domnick Cunningham & Yaffa On What the FDA’s Latest Warning to Olympus Means for Medical Device Accountability The Manila Times
26North strikes deal for Olympus Partners’ MEI Industrial Solutions - PEI Private Equity
26North strikes deal for Olympus Partners’ MEI Industrial Solutions PEI Private Equity
8-K Filing: Accelevation Holdings Corp. (ACCV) (CIK 0002141406) — EX-10.1
EX-10.1
Natco Pharma Rights Issue 2026 Date, Price, Allotment, Ratio - IPO Watch
Natco Pharma Rights Issue 2026 Date, Price, Allotment, Ratio IPO Watch
Waycen and INEX secure major partners... Competition shifts beyond technology to 'distribution' - 헬스조선
Waycen and INEX secure major partners... Competition shifts beyond technology to 'distribution' 헬스조선
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Evaluation of Computer-aided Detection for Identifying Missed Gastric Cancer After Endoscopic Submucosal Dissection.
Ameliorating Effect of Continuous Treatment With an Amorphous Formula of Curcumin on Maternal Imidacloprid Exposure-Induced Suppression of Hippocampal Neurogenesis in Rats.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo